This is due, in part, to the continued challenge of detecting very large ITDs by NGS [23,24,25] and to quickly informing oncologists of the potential benefit of using FLT3 inhibitors in the induction cocktail for AML patients [7]. This evidence concerns the gene FLT3 and acute myeloid leukemia.